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Introduction: Conventional venous blood collection requires a puncture with a needle
through the endothelium of a vessel. The endothelial injury causes activation of circulating
platelets and the release of thromboxane A2. The aim of the study was to investigate if
platelets continue to form thromboxane A2 in the blood tube after sample collection, but such
synthesis would give false information about the actual circulating thromboxane A2 value.
Methods: Thromboxane B2 is a biologically inactive but stable metabolite of thromboxane
A2 and can be measured in blood samples by a standard enzyme immunoassay.
Thromboxane B2 measurements reﬂect thromboxane A2 concentration. Blood samples
were collected in 3.2% sodium citrate vials and EDTA vials from ten individuals and
centrifuged and frozen at different time points (0, 30, and 120 minutes). Plasma aliquots
were transferred to and frozen in 1.8 mL polypropylene tubes and the citrate samples were
also transferred to and frozen in propylene tubes containing indomethacin.
Results: Concentrations of thromboxane B2 in plasma samples collected in citrate vials and
stored in propylene tubes increased very rapidly as the samples were left for longer after
sampling and allowed to stand at room temperature. After 120 minutes, the amount of
thromboxane B2 was 400% higher than in the reference sample at time zero. In comparison,
thromboxane B2 concentration was about 200% higher in the 120-minute samples compared
to the reference in samples collected in citrate vials but stored in indomethacin tubes. In
samples collected in EDTA vials, a 10% reduction in thromboxane B2 concentration in the
120-minute samples was observed.
Conclusion: Storage conditions, type of sampling vial and time from sampling until sample
processing (centrifuging) has a major impact on thromboxane B2 stability.
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Introduction
Platelets or thrombocytes are disk-shaped cells circulating in the blood stream with
a lifespan of about 10 days. They have no cell nucleus and are produced by
megakaryocytes in the bone marrow.1 A normal platelet count ranges from 150 to
400×109/L1,2 and they are involved in the initial cellular response to endothelial
damage and repairing the vessel. Platelet function that depends on platelet throm-
boxane production can be determined by measuring platelet thromboxane A2
(TxA2) release.
3 Activated platelets convert arachidonic acid to TxA2 by the
enzyme cyclooxygenase (COX-1).4 TxA2 stimulates platelet aggregation as well
as smooth muscle contraction.5 Consequently, TxA2 has both prothrombic proper-
ties as well as being a potent vasoconstrictor.
Measuring thromboxane in blood samples is useful for evaluating the efﬁcacy of
acetylsalicylic acid (aspirin) since it inhibits irreversibly the platelet COX, prevent-
ing the formation of prostaglandin H2 and therefore TxA2.
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TxA2 is very unstable under physiological conditions and
is rapidly degraded into an inactive metabolite called throm-
boxane B2 (TxB2).
4 TxA2 has a half-life of about 30 seconds,
where TxB2 has a half-life of 5–7 minutes whereafter it is
rapidly metabolized to urinary metabolites such as 11-dehy-
drothromboxane B2. Due to the ultra-short half-life TxA2
cannot be analyzed in blood samples. TxB2 and 11-dehydro-
thromboxane B2, however, can be measured with various
methods such as gas and liquid chromatography, mass spec-
troscopy and enzyme immunoassays. The concentrations of
TxB2 or the urinary metabolite 11-dehydrothromboxane B2
are used to reﬂect the levels of its source, TxA2.
3,7
The collection of a blood sample requires a puncture
through the endothelium of a vessel with a needle, result-
ing in that local platelets are activated and start to produce
TxA2. The platelets that are collected into the tube are,
therefore, in an activated state and may continue to pro-
duce TxA2 inside the tube. This may give false informa-
tion about the true TxA2 value in the circulation.
The aim of this study was to study the stability of TxB2
in blood samples by measuring possible exnuovo produc-
tion of TxA2 in blood samples. Samples were collected in
two different blood tubes and consequently processed and
frozen at different time points. TxB2 concentration was
then measured using standardized enzyme immunoassay.
Optimizing a method for handling platelets is complicated,
involving many different factors, including heat sensitiv-
ity, time-dependent differences and factors due to antic-
oagulants and plasma preparation.8,9 The method used in
this study was set up based on standard procedures recom-
mended by the Clinical Department of the Icelandic
University Hospital, Landspitali.
Materials and methods
The study was approved by the Ethics Committee at
Landspitali University Hospital in Iceland (No. 22/2016).
All participants provided written informed consent after
receiving information about the study in accordance with
the Declaration of Helsinki.
Blood sample collection and preparation
Ten healthy volunteers with body mass index (BMI) under
30 kg/m2 participated in the study. All participants were
free of any medication considered to affect the coagulation
process, such as aspirin or nonsteroidal anti-inﬂammatory
drugs (NSAIDs) at least one week prior to participation in
the study and all participants were nonsmokers. Blood
samples from each participant were collected in a total of
seven blood tubes; (i) three Vacuette® blood tubes
(Greiner Bio-One GmbH, Kremsmünster, Austria) con-
taining 3.2% sodium citrate; and (ii) four tubes containing
EDTA. One of the EDTA blood samples was collected to
measure complete blood count using Sysmex XE-5000
hematology instrument (Sysmex XE-5000 analyzer;
Sysmex, Kobe, Japan). The other six samples were cen-
trifuged at 3,200 rpm for 14 minutes at 4°C.
After centrifugation, the plasma was aliquoted into 1.8
mL polypropylene tubes or in sampling tubes containing
10 µm indomethacin (Cayman Chemicals, Ann Arbor, MI,
USA, No. 10,951). Indomethacin is a COX inhibitor that
prevents ex-vivo thromboxane formation that cannot be
prevented using anticoagulant alone. The samples stored
in tubes containing indomethacin were stored frozen at
−20°C. Samples stored in polypropylene tubes were frozen
immediately in dry ice and then stored at −80°C.
The whole blood samples collected in vials containing
citrate, and three of the whole samples collected in EDTA
vials were centrifuged and plasma aliquoted at following
times: Right after blood collection (0 minutes), 30 min-
utes, and 120 minutes after blood withdrawal (samples
were allowed to stand at room temperature (23°C) until
centrifugation).
TxB2 measurements
Concentration of TxB2 was measured using commercially
available reagents from Cayman Chemicals (Ann Arbor, MI,
USA), No. 501020. The measuring method is a competitive
enzyme immunoassay (EIA) based in the competition between
TxB2 and a TxB2-acetylcholinesterase (AChE) conjugate
(TxB2 tracer) for a limited number of TxB2-speciﬁc rabbit
antiserum binding sites. The concentration of the TxB2 tracer
is held constant, thus the concentration of TxB2 is inversely
proportional to the concentration of TxB2 on the well. The
method can be used for quantiﬁcation of TxB2 in urine, serum,
plasma, culture media samples, and other sample matrices.
Plasma (citrate and EDTA) was used in this study. The EIA
displays an IC50 of approximately 60 pg/mL and has a detec-
tion limit of 5 pg/mL. Standards, buffers, washing buffer, and
all other solutions supplied with the kits were used as recom-
mended from the manufacturer.3
Statistics
To get 80% power in the study with 5% acceptance for
type 1 error, number of subjects were calculated based on
statistical method for qualitative outcome.10 The p1 value
was deﬁned as zero (proportion of the control expected to
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be more than zero), since subjects act as their own control.
The p2 value was set to 50% (proportion of the study
group expected to show change compared to control).
Total number of subjects needed based on the calculations
were eight. Since sampling, measurement and quantiﬁca-
tion of TxB2 is a very delicate procedure two more parti-
cipants were added to the study, resulting in a total of ten
volunteers participating in the study.
Results are expressed as percentage change from the
reference (0 minutes) sample. Results are expressed as
mean ±SEM of N were N is the number of participants.
Student's t-test was used to analyze the difference in rela-
tive concentration of TxB2 between groups and P<0.05
was considered as signiﬁcant.
Results
Total number of participants were ten, six females and four
males. Table 1 summarizes the main characteristics of the
participants in the study. Blood status values of all parti-
cipants were within normal range. No correlation was
found between platelet count and the TxB2 levels.
Figure 1 shows that both the type of blood vials (citrate
or EDTA) and the storage conditions (with or without
indomethacin) of the plasma samples are important for
TxB2 measurements. The individual variation was found
to be high, especially for samples collected in citrate tubes
and stored in the empty polyethylene tubes.
Citrate plasma samples stored in the empty polyethy-
lene tubes (cit-emp) showed 40% increase in TxB2 levels
in samples processed after 30 minutes compared to the
reference sample at time zero. In the 120-minute samples,
however, the increase reached an average of 400% com-
pared to the time zero sample.
Citrate plasma samples stored in indomethacin tubes
(cit-indo) were more stable compared to the cit-emp sam-
ples. The increase was found to be similar (Figure 1) in the
30-minute cit-indo and cit-emp samples. However, in the
120-minute samples the increase in the cit-indo was about
200% compared to the reference sample. There was a
statistical difference between the cit-emp and cit-indo sto-
rage tubes in the 120-minute samples (P=0.038).
EDTA plasma samples had the least variation, where
there was on average no increase in the TxB2 concentra-
tion over the studied range. On the contrary, there was
about 10% decrease in the concentration detected at 30
minutes and 120 minutes compared to the zero sample.
The difference at 120 minutes was statistically signiﬁcant
Table 1 Characteristics of participants in the study
Characteristics Total Male Female
Total number of participants, %
(N)
100 (10) 40 (4) 60 (6)
Age (years), mean ±SD 27.0±5.6 24.8±4.2 28.5±6.3
BMI, mean ±SD 23.2±3.3 24.2±3.1 22.6±3.5
Platelets (count) [109/L], mean
±SD
231.4
±40.8
219.3
±35.1
239.5
±45.4
Abbreviation: BMI, body mass index.
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Figure 1 Relative change in thromboxane B2 concentration.
Notes: EDTA plasma samples stored in empty polypropylene tubes. Samples were processed at 0, 30, and 120 minutes after blood collection. Data are reported as mean ±
SEM.
Abbreviations: Cit-emp, citrate plasma samples stored in empty polypropylene tubes; Cit-indo, citrate plasma samples stored in indomethacin tubes.
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when compared to cit-emp (P<0.001) and compared to cit-
indo (P=0.001) samples.
Discussion and conclusion
The results indicate that the time from sampling to storage
is an important factor for thromboxane B2 stability. The
type of sampling tubes as well as the storage conditions
were also found to have a great impact on the true TxB2 in
the blood samples.
The cit-emp tubes showed up to 400% increase in
TxB2 concentration, indicating that there is a signiﬁcant
ex-nuovo formation of TxB2 after the samples have been
collected and frozen. The cit-indo tubes also showed a
high increase in the TxB2 formation post sampling,
although the indomethacin tubes showed less TxB2 forma-
tion compared to the cit-emp tubes.
Interestingly, there was no ex-nuovo TxB2 formation in
the EDTA plasma samples even though these samples
were stored in polypropylene tubes containing no indo-
methacin. Citrate and EDTA are both anticoagulants used
in vitro to prevent clot formation in blood samples.
Calcium is essential for normal platelet adherence and
for a wide range of enzyme reactions of the coagulation
cascade. Removing it prevents blood clotting within the
blood collection tube.11 EDTA is a polyprotic acid contain-
ing four carboxylic acid groups and two amine groups
with lone-pair electrons that chelate calcium and several
other metal ions in 1:1 metal-EDTA complexes.12 Sodium
citrate is the sodium salt of citric acid with alkalinizing
activity. Citrate also acts by removing calcium from the
blood sample, but unlike EDTA, it is reversible. Residual
calcium ions are not expected to be present in samples in
the EDTA tube since the excess amount of EDTA irrever-
sibly forms 1:1 complex with calcium ions in the sample.
When collecting blood samples in sodium citrate tubes the
ratio between the blood sample (thus calcium) and sodium
citrate in the tube is important. If the ratio is shifted
residual calcium ions are expected to be present. This
possible imbalance was minimized by ﬁlling the tube
with enough whole blood, and by trying to have the
amount as equal as possible between each tube.
Previous study suggested that EDTA is capable of
penetrating biological membranes such as plasma mem-
branes to chelate intracellular calcium to prevent platelet
activation.13 However further studies have shown that in
vitro activation does occur in EDTA-anticoagulated
blood.8 Thus, the extent of this factor on the overall results
of this particular study is not clear.
In conclusion, these results are interesting since both
citrate and EDTA are able to bind calcium ions in the
blood. The different mechanism behind the calcium
removal in the blood sample might play a crucial role in
the stability of TxB2 in the samples. It has also been
shown that acidity has an effect on the coagulation,
where lowering the pH reduces coagulation.14 The acidity
of the plasma might also be of importance. These results
are important for future analysis and work with TxB2.
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